TRULIEVE CANNABIS Logo
CA89788C1041
A2N60S
TRUL.CN

TRULIEVE CANNABIS

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 43,02 € (+404,34 %). La mediana es de 48,23 € (+465,42 %).

Comprar
  9
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Trulieve beats Q2 earnings forecast, revenue slightly below expectations and shares fall

    Trulieve reported adjusted Q2 earnings of $0.11 per share versus the consensus estimate of $0.08, while revenue of $271 million was just below the expected $272.21 million. Gross margin was 60% and adjusted EBITDA margin 36%; operations generated $53 million in operating cash flow and $32 million in free cash flow. A one‑time effect from the deconsolidation of Harvest caused a GAAP net loss of $406 million; on an adjusted basis Trulieve posted net income of $20 million. The company ended the quarter with $325 million in cash and $289 million in debt (net cash $36 million) and lowered its full‑year forecast for operating cash flow to at least $225 million while increasing CAPEX to $95 million. In premarket trading the stock was at $8.91, about 1% below the prior close. » Más en de.investing.com


  • Trulieve Cannabis rises premarket after Q2 report and first balance-sheet impact of reclassification

    Trulieve Cannabis stock climbed premarket after the company released its Q2 2026 results. It is the first full reporting period since medical cannabis was downgraded from Schedule I to Schedule III, removing the burden of Section 280E. Analyst consensus expects about $0.08 earnings per share on roughly $272 million in revenue; management will explain the results on a conference call at 8:30 a.m. ET. Institutional interest has increased since the NYSE uplisting, and seven analysts recommend buying ahead of the release. » Más en de.investing.com


  • Trulieve CEO sells $1.2 million in stock after 148% one-year rally

    Kim Rivers sold 136,811 direct shares for about $1.2 million on June 26, 2026, the final tranche of several sales executed between June 17 and June 26. Rivers retains significant indirect voting power via Traunch IV LLC, suggesting continued alignment with the company. The sale follows a roughly 148% one-year share gain and recent operational momentum, including Q1 revenue strength, positive net income and cash generation, and approval to list on the New York Stock Exchange after rescheduling to Schedule III. » Más en finance.yahoo.com


  • Trulieve becomes first US plant-touching cannabis company to list on NYSE

    Florida-based Trulieve began trading on the NYSE under ticker TRLV, jumping about 4% on its first day as shares traded near $12. The uplisting follows the reclassification of medical cannabis to Schedule III, which opened a path for US cultivators to list on major exchanges after previously trading OTC or in Canada. Trulieve separated its medical and recreational assets to satisfy regulators and holds roughly 30–40% of Florida’s medical cannabis revenue, while competitors prepare for possible uplistings ahead of a DEA hearing on June 29 that could further change the industry’s prospects. » Más en finance.yahoo.com


  • Trulieve launches up to $50 million share buyback program

    Trulieve has approved a 12‑month buyback program to acquire common shares worth up to $50 million or a maximum of 8,495,038 shares (whichever is lower), representing about 5% of outstanding shares. The program runs until June 16, 2027; repurchased shares will be cancelled and purchases will be made in accordance with applicable securities laws. Management emphasizes confidence in the company’s long‑term value; the stock is trading near its 52‑week high and analysts see a possible return to profitability later this year. » Más en de.investing.com

En 2022, TRULIEVE CANNABIS ya ha pagado 0,15 € en dividendos. El último pago fue en mayo de 2022.

Datos financieros de la empresa

En el último trimestre, TRULIEVE CANNABIS tuvo unos ingresos de 203,25 M € y un beneficio neto de 767,2 mil €
(EUR) septiembre de 2026
YoY
Ingresos 203,25 M 17,24 %
Beneficio bruto 130,68 M 9,71 %
Beneficio neto 767,2 mil 103,39 %
EBITDA 29 M 61,67 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
2146,78 M €
Número de acciones
192,31 M
Máximo/mínimo de 52 semanas
12,10 € - 7,22 €
Dividendos No
Beta
1,68
Ratio P/E
-4,37
Ratio PEG
0,05
Ratio P/B
2,51
Ratio P/S
1,59

Perfil de la empresa

Trulieve Cannabis Corp., junto con sus subsidiarias, opera como una empresa de cannabis medicinal. Cultiva y produce sus productos internamente y los distribuye a tiendas de marca Trulieve (dispensarios) en Florida, así como mediante entrega a domicilio. La empresa produce flores, comestibles, cartuchos para vaporizadores, concentrados, productos tópicos, cápsulas, tinturas, polvos solubles y aerosoles nasales bajo las marcas Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli y Roll One. A 16 de marzo de 2022, operaba 162 dispensarios, de los cuales 113 estaban en Florida, 19 eran dispensarios afiliados en Pensilvania, 17 en Arizona, cinco en California, tres en Maryland, dos en Massachusetts, dos en Virginia Occidental y uno en Connecticut. Trulieve Cannabis Corp. también operaba instalaciones de cultivo y procesamiento en Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pensilvania y Virginia Occidental. La empresa era anteriormente conocida como Schyan Exploration Inc. / Exploration Schyan Inc. y cambió su nombre a Trulieve Cannabis Corp. en septiembre de 2018. Trulieve Cannabis Corp. se constituyó en 1940 y tiene su sede en Quincy, Florida.

Nombre
TRULIEVE CANNABIS
CEO
Kimberly Rivers
Sede Tallahassee, fl
Estados Unidos
Sitio web
Sector
Servicios públicos
Industria
Productos de cuidado personal
Salida a bolsa
10/07/2017
Empleados 6000

Símbolos bursátiles

Bolsa Símbolo
Cnq
TRUL.CN
Pnk
TCNNF
Frankfurt
T0A.F
Düsseldorf
T0A.DU
München
T0A.MU
🍪

Parqet  usa cookies. Más información